Avadel Pharmaceuticals plc (AVDL)
USD 8.31
(0.48%)
USD 8.31
(0.48%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 173.38 Million USD | 12.64% |
| 2022 | 153.93 Million USD | -8.93% |
| 2021 | 169.02 Million USD | 13.16% |
| 2020 | 149.37 Million USD | -17.31% |
| 2019 | 180.63 Million USD | -3.67% |
| 2018 | 187.52 Million USD | 11.92% |
| 2017 | 167.54 Million USD | -17.63% |
| 2016 | 203.41 Million USD | 38.27% |
| 2015 | 147.11 Million USD | -1.47% |
| 2014 | 149.31 Million USD | 18.72% |
| 2013 | 125.76 Million USD | 44.88% |
| 2012 | 86.8 Million USD | 119.17% |
| 2011 | 39.6 Million USD | 3.39% |
| 2010 | 38.3 Million USD | -22.5% |
| 2009 | 49.43 Million USD | 14.12% |
| 2008 | 43.31 Million USD | -7.4% |
| 2007 | 46.77 Million USD | 11.72% |
| 2006 | 41.86 Million USD | 11.06% |
| 2005 | 37.69 Million USD | 30.66% |
| 2004 | 28.85 Million USD | -18.02% |
| 2003 | 35.19 Million USD | 226.14% |
| 2002 | 10.79 Million USD | 1.46% |
| 2001 | 10.63 Million USD | 12.21% |
| 2000 | 9.47 Million USD | 61.93% |
| 1999 | 5.85 Million USD | -22.3% |
| 1998 | 7.53 Million USD | 4.63% |
| 1997 | 7.2 Million USD | 5.88% |
| 1996 | 6.8 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 89.51 Million USD | -48.37% |
| 2024 Q2 | 87.23 Million USD | -2.55% |
| 2023 Q4 | 173.38 Million USD | 86.54% |
| 2023 Q1 | 178.9 Million USD | 16.22% |
| 2023 Q3 | 92.95 Million USD | 60.86% |
| 2023 FY | 173.38 Million USD | 12.64% |
| 2023 Q2 | 57.78 Million USD | -67.7% |
| 2022 Q4 | 153.93 Million USD | -2.7% |
| 2022 FY | 153.93 Million USD | -8.93% |
| 2022 Q1 | 165.89 Million USD | -1.85% |
| 2022 Q2 | 161.27 Million USD | -2.79% |
| 2022 Q3 | 158.19 Million USD | -1.9% |
| 2021 Q3 | 165.13 Million USD | 0.87% |
| 2021 Q4 | 169.02 Million USD | 2.36% |
| 2021 Q1 | 156.43 Million USD | 4.73% |
| 2021 FY | 169.02 Million USD | 13.16% |
| 2021 Q2 | 163.71 Million USD | 4.65% |
| 2020 FY | 149.37 Million USD | -17.31% |
| 2020 Q1 | 175.65 Million USD | -2.76% |
| 2020 Q2 | 159.27 Million USD | -9.33% |
| 2020 Q3 | 156.43 Million USD | -1.78% |
| 2020 Q4 | 149.37 Million USD | -4.52% |
| 2019 Q3 | 182.85 Million USD | -0.35% |
| 2019 Q1 | 183.2 Million USD | -2.3% |
| 2019 FY | 180.63 Million USD | -3.67% |
| 2019 Q4 | 180.63 Million USD | -1.21% |
| 2019 Q2 | 183.48 Million USD | 0.15% |
| 2018 Q2 | 216.69 Million USD | -18.17% |
| 2018 Q1 | 264.8 Million USD | 58.05% |
| 2018 Q4 | 187.52 Million USD | -7.75% |
| 2018 Q3 | 203.26 Million USD | -6.2% |
| 2018 FY | 187.52 Million USD | 11.92% |
| 2017 Q2 | 182.43 Million USD | -8.6% |
| 2017 Q4 | 167.54 Million USD | -7.42% |
| 2017 FY | 167.54 Million USD | -17.63% |
| 2017 Q1 | 199.6 Million USD | -1.87% |
| 2017 Q3 | 180.96 Million USD | -0.8% |
| 2016 Q3 | 211.15 Million USD | 6.71% |
| 2016 Q4 | 203.41 Million USD | -3.67% |
| 2016 Q2 | 197.86 Million USD | 6.78% |
| 2016 FY | 203.41 Million USD | 38.27% |
| 2016 Q1 | 185.31 Million USD | 25.97% |
| 2015 FY | 147.11 Million USD | -1.47% |
| 2015 Q1 | 164.16 Million USD | 9.95% |
| 2015 Q2 | 172.9 Million USD | 5.33% |
| 2015 Q4 | 147.11 Million USD | 0.0% |
| 2014 Q3 | 124.33 Million USD | 6.48% |
| 2014 Q4 | 149.31 Million USD | 20.09% |
| 2014 Q2 | 116.76 Million USD | 12.7% |
| 2014 FY | 149.31 Million USD | 18.72% |
| 2014 Q1 | 103.61 Million USD | -17.61% |
| 2013 Q1 | 101.05 Million USD | 16.41% |
| 2013 Q2 | 128.47 Million USD | 27.14% |
| 2013 Q3 | 131.91 Million USD | 2.68% |
| 2013 Q4 | 125.76 Million USD | -4.67% |
| 2013 FY | 125.76 Million USD | 44.88% |
| 2012 Q4 | 86.8 Million USD | 0.0% |
| 2012 Q2 | 108.35 Million USD | 2.78% |
| 2012 FY | 86.8 Million USD | 119.17% |
| 2012 Q1 | 105.42 Million USD | 166.17% |
| 2011 FY | 39.6 Million USD | 3.39% |
| 2011 Q1 | 35.96 Million USD | -6.13% |
| 2011 Q2 | 44.22 Million USD | 22.97% |
| 2011 Q3 | 40.33 Million USD | -8.79% |
| 2011 Q4 | 39.6 Million USD | -1.8% |
| 2010 Q1 | 42.34 Million USD | -14.34% |
| 2010 FY | 38.3 Million USD | -22.5% |
| 2010 Q4 | 38.3 Million USD | -12.77% |
| 2010 Q3 | 43.91 Million USD | 15.22% |
| 2010 Q2 | 38.11 Million USD | -9.99% |
| 2009 Q3 | 47.85 Million USD | 10.51% |
| 2009 Q4 | 49.43 Million USD | 3.31% |
| 2009 FY | 49.43 Million USD | 14.12% |
| 2009 Q1 | 42.03 Million USD | -2.95% |
| 2009 Q2 | 43.3 Million USD | 3.01% |
| 2008 Q3 | 38.1 Million USD | -13.85% |
| 2008 FY | 43.31 Million USD | -7.4% |
| 2008 Q1 | 47.87 Million USD | 2.35% |
| 2008 Q2 | 44.23 Million USD | -7.61% |
| 2008 Q4 | 43.31 Million USD | 13.68% |
| 2007 FY | 46.77 Million USD | 11.72% |
| 2007 Q4 | 46.77 Million USD | -3.52% |
| 2007 Q3 | 48.47 Million USD | 2.17% |
| 2007 Q2 | 47.45 Million USD | 17.33% |
| 2007 Q1 | 40.44 Million USD | -3.4% |
| 2006 Q3 | 39.34 Million USD | 14.79% |
| 2006 Q4 | 41.86 Million USD | 6.42% |
| 2006 Q2 | 34.27 Million USD | 1.45% |
| 2006 Q1 | 33.78 Million USD | -10.38% |
| 2006 FY | 41.86 Million USD | 11.06% |
| 2005 Q2 | 37.47 Million USD | 29.25% |
| 2005 FY | 37.69 Million USD | 30.66% |
| 2005 Q4 | 37.69 Million USD | 12.71% |
| 2005 Q3 | 33.44 Million USD | -10.76% |
| 2005 Q1 | 28.99 Million USD | 0.51% |
| 2004 Q4 | 28.85 Million USD | -8.28% |
| 2004 Q3 | 31.45 Million USD | 0.0% |
| 2004 FY | 28.85 Million USD | -18.02% |
| 2004 Q1 | 33.58 Million USD | -4.57% |
| 2004 Q2 | 31.45 Million USD | -6.33% |
| 2003 FY | 35.19 Million USD | 226.14% |
| 2003 Q4 | 35.19 Million USD | 180.56% |
| 2003 Q2 | 13.21 Million USD | 5.63% |
| 2003 Q1 | 12.51 Million USD | 15.95% |
| 2003 Q3 | 12.54 Million USD | -5.09% |
| 2002 Q3 | 9.71 Million USD | 0.0% |
| 2002 FY | 10.79 Million USD | 1.46% |
| 2002 Q4 | 10.79 Million USD | 11.05% |
| 2001 Q4 | 10.63 Million USD | 0.0% |
| 2001 FY | 10.63 Million USD | 12.21% |
| 2000 Q4 | 9.47 Million USD | 0.0% |
| 2000 FY | 9.47 Million USD | 61.93% |
| 1999 Q4 | 5.85 Million USD | 0.0% |
| 1999 FY | 5.85 Million USD | -22.3% |
| 1998 Q4 | 7.53 Million USD | 0.0% |
| 1998 Q1 | 7.5 Million USD | 4.17% |
| 1998 FY | 7.53 Million USD | 4.63% |
| 1997 FY | 7.2 Million USD | 5.88% |
| 1997 Q4 | 7.2 Million USD | 0.0% |
| 1996 Q4 | 6.8 Million USD | 0.0% |
| 1996 FY | 6.8 Million USD | 0.0% |
| 1996 Q1 | 6.2 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aquestive Therapeutics, Inc. | 163.9 Million USD | -5.785% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 81.708% |
| Journey Medical Corporation | 56.49 Million USD | -206.885% |
| Dynavax Technologies Corporation | 375.02 Million USD | 53.766% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 73.761% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | -26.679% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 75.38% |
| PainReform Ltd. | 2.69 Million USD | -6343.218% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -713.421% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -2724.076% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -2724.076% |
| SCYNEXIS, Inc. | 55.45 Million USD | -212.691% |
| Silver Spike Investment Corp. | 3 Million USD | -5660.689% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -1785.336% |
| Alpha Teknova, Inc. | 38.55 Million USD | -349.76% |
| Alvotech | 1.88 Billion USD | 90.79% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 63.24% |
| Bright Green Corporation | 6.43 Million USD | -2593.138% |
| Embecta Corp. | 2.03 Billion USD | 91.484% |
| Safety Shot Inc | 3.89 Million USD | -4354.909% |
| Procaps Group, S.A. | 462.06 Million USD | 62.476% |
| Cosmos Health Inc. | 30.25 Million USD | -473.132% |
| Theratechnologies Inc. | 98.63 Million USD | -75.779% |
| Harrow Health, Inc. | 241.75 Million USD | 28.279% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -1880.208% |
| Biofrontera Inc. | 23.13 Million USD | -649.328% |
| DURECT Corporation | 30.4 Million USD | -470.239% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 64.431% |
| Cronos Group Inc. | 43.73 Million USD | -296.439% |
| OptiNose, Inc. | 194.33 Million USD | 10.779% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 78.787% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -257.905% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -726.513% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 4.397% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -4496.523% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -230.159% |
| Radius Health, Inc. | 804.29 Million USD | 78.442% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -1160.599% |
| ProPhase Labs, Inc. | 42.54 Million USD | -307.547% |
| Phibro Animal Health Corporation | 725.54 Million USD | 76.102% |
| Procaps Group S.A. | 462.06 Million USD | 62.476% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -1136.535% |
| Viatris Inc. | 27.21 Billion USD | 99.363% |
| Rockwell Medical, Inc. | 30.88 Million USD | -461.45% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -91.844% |
| SIGA Technologies, Inc. | 57.97 Million USD | -199.06% |
| Tilray Brands, Inc. | 892.11 Million USD | 80.565% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 21.116% |
| Shineco, Inc. | 47.6 Million USD | -264.246% |
| PetIQ, Inc. | 645.22 Million USD | 73.128% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -78887.481% |
| Incannex Healthcare Limited | 5.83 Million USD | -2874.048% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 82.991% |
| Alimera Sciences, Inc. | 107.35 Million USD | -61.51% |
| Assertio Holdings, Inc. | 148.41 Million USD | -16.825% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -9045.053% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -2367.791% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -1942.122% |
| Hempacco Co., Inc. | 18.82 Million USD | -821.173% |
| Talphera, Inc. | 6.29 Million USD | -2656.55% |
| Alvotech | 1.88 Billion USD | 90.79% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | -0.456% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 79.241% |
| Currenc Group, Inc. | 177.67 Million USD | 2.414% |
| Kamada Ltd. | 109.96 Million USD | -57.67% |
| Indivior PLC | 1.95 Billion USD | 91.114% |
| Evoke Pharma, Inc. | 9.64 Million USD | -1697.113% |
| Flora Growth Corp. | 17.22 Million USD | -906.776% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -1942.122% |
| Evolus, Inc. | 209.68 Million USD | 17.312% |
| HUTCHMED (China) Limited | 536.38 Million USD | 67.675% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 80.15% |
| Akanda Corp. | 12.66 Million USD | -1268.605% |